What are the differences between NSAID-induced peptic ulcer and ulcerative gastritis?

NSAID-Induced Peptic Ulcer vs. Ulcerative Gastritis: Key Distinctions

NSAID-induced peptic ulcer and ulcerative gastritis (chemical gastropathy) are distinct entities—peptic ulcers are discrete, full-thickness mucosal defects that carry significant risk of bleeding, perforation, and mortality, while chemical gastritis represents superficial histologic changes that are poorly correlated with clinical outcomes and rarely present in NSAID users.

Pathophysiologic and Clinical Differences

NSAID-Induced Peptic Ulcer Disease

Peptic ulcers are focal, deep mucosal lesions that penetrate through the muscularis mucosae and represent the primary source of serious NSAID-related morbidity and mortality. 1, 2

• Prevalence: 10-30% of chronic NSAID users develop gastric ulcers on endoscopy, with approximately 0.75% developing clinically significant complications (bleeding, perforation, obstruction) within 6 months 3
• Location: Predominantly in the prepyloric region (28%) and antrum (62%), with 31% of patients having multiple ulcers 4
• Mechanism: Results from COX enzyme inhibition leading to impaired prostaglandin synthesis and compromised mucosal defense, plus direct mucosal injury 1
• H. pylori relationship: NSAID-associated gastric ulcers have a significantly lower H. pylori prevalence (53%) compared to non-NSAID ulcers (83%), indicating these ulcers develop through a distinct mechanism that does not require H. pylori 5
• Clinical significance: These are the lesions responsible for major bleeding, perforation, and gastric outlet obstruction 3

Chemical Gastritis (Reactive Gastropathy)

Chemical gastritis is a histologic diagnosis characterized by foveolar hyperplasia and smooth muscle fiber proliferation, but it is present in only a minority of NSAID users and does not correlate with ulcer formation or clinical complications. 6, 7

• Prevalence: Present in only 9-34% of chronic NSAID users versus 5-18% of controls—a statistically significant but clinically modest difference 6, 7
• Histologic features: Foveolar hyperplasia (absent in 66% of NSAID users), smooth muscle fibers in lamina propria, edema—but no single feature is diagnostic 7
• Clinical correlation: Chemical gastritis is not strongly correlated with NSAID-induced damage, ulcer prevalence, or hemorrhagic events 6
• Inflammatory infiltrate: NSAIDs do not cause diffuse inflammatory cell infiltration; any such gastritis is due to H. pylori infection, not NSAID ingestion 3
• Diagnostic limitation: Reactive gastritis was found in only 2 of 96 RA patients on continuous NSAIDs, indicating it is rarely associated with chronic NSAID use 4

Critical Clinical Distinctions

Histologic vs. Endoscopic Findings

• NSAID users with gastric ulcers have significantly less histologic gastritis at the ulcer rim compared to non-NSAID ulcers, with inflammation and epithelial abnormality scores being lower in NSAID-associated ulcers 5
• H. pylori-negative NSAID patients have minimal histologic inflammation (score 0.6 ± 0.2) compared to H. pylori-positive patients (2.4 ± 0.4), confirming that gastritis is related to H. pylori, not NSAIDs 5
• The spectrum of erosions and subepithelial hemorrhages represents superficial damage that may cause minor bleeding but does not lead to major complications unless ulcers are present 3

Risk Stratification

The presence or absence of chemical gastritis has no role in risk stratification for NSAID complications—focus instead on established risk factors for peptic ulcer disease. 8

Key risk factors for NSAID-induced peptic ulcers include:

• Advanced age 1, 2
• History of peptic ulcer or GI bleeding 8, 1
• Corticosteroid use (independent risk factor with OR 6.8) 4
• Concomitant anticoagulants or antiplatelet agents 8, 2
• Higher NSAID doses 3

Management Implications

Prevention Strategy

Base gastroprotection decisions on ulcer risk factors, not on the presence or absence of chemical gastritis, which has no predictive value. 8

• High-risk patients: Combination of selective COX-2 inhibitor plus PPI 9
• Moderate-risk patients: Either NSAID plus PPI or selective COX-2 inhibitor alone 9
• PPI cotherapy reduces endoscopic NSAID-related ulcers by 90%, though this is based on endoscopic endpoints rather than clinical outcomes 8
• H. pylori eradication decreases peptic ulcer incidence in NSAID-naive patients but protective effects do not extend to those with previous ulcer history 8, 10

Common Pitfalls

• Do not rely on histologic findings of chemical gastritis to diagnose or predict NSAID-related complications—the correlation is poor and many patients with serious ulcers lack these histologic changes 6, 7
• Do not assume that absence of symptoms indicates absence of risk—there is no correlation between upper abdominal symptoms and NSAID gastropathy 3
• Do not attribute all gastritis in NSAID users to the medication—concurrent H. pylori infection obscures and accounts for most inflammatory changes 7, 5